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Alejandro López-Juárez,1,4 Haley E. Titus,1,4 Sadiq H. Silbak,1 Joshua W. Pressler,1 Tilat A. Rizvi,1 Madeleine Bogard,1
Michael R. Bennett,1 Georgianne Ciraolo,2 Michael T. Williams,3 Charles V. Vorhees,3 and Nancy Ratner1,5,*
1Division

of Experimental Hematology and Cancer Biology
of Pathology
3Division of Neurology
Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
4These authors contributed equally
5Lead Contact
*Correspondence: nancy.ratner@cchmc.org
http://dx.doi.org/10.1016/j.celrep.2017.03.073
2Division

SUMMARY

The RASopathy neurofibromatosis type 1 (NF1) is
one of the most common autosomal dominant genetic disorders. In NF1 patients, neurological issues
may result from damaged myelin, and mice with a
neurofibromin gene (Nf1) mutation show white matter (WM) defects including myelin decompaction.
Using mouse genetics, we find that altered Nf1
gene-dose in mature oligodendrocytes results in
progressive myelin defects and behavioral abnormalities mediated by aberrant Notch activation.
Blocking Notch, upstream mitogen-activated protein
kinase (MAPK), or nitric oxide signaling rescues
myelin defects in hemizygous Nf1 mutants, and pharmacological gamma secretase inhibition rescues
aberrant behavior with no effects in wild-type (WT)
mice. Concomitant pathway inhibition rescues
myelin abnormalities in homozygous mutants. Notch
activation is also observed in Nf1+/ mouse brains,
and cells containing active Notch are increased in
NF1 patient WM. We thus identify Notch as an Nf1
effector regulating myelin structure and behavior in
a RASopathy and suggest that inhibition of Notch
signaling may be a therapeutic strategy for NF1.
INTRODUCTION
The RASopathy neurofibromatosis type 1 (NF1) is one of the
most common autosomal dominant genetic disorders. NF1
gene mutation, alone or with subsequent loss of the previously
normal somatic allele, can lead to a variety of conditions in
NF1 patients, ranging from aesthetic issues such as epidermal
hyperpigmentation, to disabling bone malformations and
aggressive life-threatening tumors (Ratner and Miller, 2015).
NF1-associated neurological abnormalities include learning deficits, delayed acquisition of motor skills, and attention-deficit

disorder, with or without hyperactivity; autism manifestations
may also be present (Acosta et al., 2006; Garg et al., 2015).
Cognitive dysfunction is the most common complication
affecting the quality of life of children and adolescents with
NF1 (Hyman et al., 2005), many of whom require neuropsychological assessment for educational planning (Acosta et al., 2012).
Significant advances have been made toward understanding
how Nf1 mutation impacts neurons, and treatments to ameliorate neuronal abnormalities have been proposed. In animal
models, activity of hippocampal interneurons (Cui et al., 2008)
and dopaminergic neurons (Diggs-Andrews et al., 2013) are
affected by Nf1 mutation. Notably, correlated abnormal behaviors are rescued by treatment with statins (Li et al., 2005) and
dopamine re-uptake inhibitors (Brown et al., 2010), respectively.
Nevertheless, mixed results in clinical studies (Bearden et al.,
2016; van der Vaart et al., 2013, 2016), along with possible memory-associated side effects (Strom et al., 2015), have precluded
definitive recommendation of the use of statins in NF1 patients.
Therefore, better understanding of molecular mechanisms underlying NF1 neurological issues is crucial to establish successful treatment regimens.
In addition to neuronal defects, 60%–70% of children with NF1
show white matter (WM) abnormalities, including enlarged brain
WM tracts, T2 hyperintensities, and altered fractional anisotropy
and diffusivity on diffusion tensor imaging (DTI) (Karlsgodt et al.,
2012; North, 2000). Myelin produced by mature oligodendrocytes (mOLs) increases nerve impulse velocity; thus, normal
brain function requires normal myelin and oligodendrocyte function (Franklin and Gallo, 2014). Indeed, learning and motor skill
acquisition correlate with changes in WM and myelin (McKenzie
et al., 2014). Nonetheless, research on effects of Nf1 loss in
mOLs is limited. We reported nitric oxide (NO)-mediated myelin
decompaction >1 year after Nf1 inactivation, correlating with
decreased tight junction (TJ) and GAP-junction (GJ) proteins
(Mayes et al., 2013). However, what signaling pathways cause
these phenotypes and whether loss of Nf1 in oligodendrocytes
causes behavioral changes is unknown.
Nf1 is a RAS GTPase-activating protein, so that loss of Nf1 results in increased RAS-mitogen-activated protein kinase (MAPK)
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Figure 1. Progressive Myelin Decompaction Regulated by MAPK Signaling in pNf1 Mutants
(A and B) Electron micrographs of the corpus callosum (CC) of WT, pNf1f/+, and pNf1f/f mice show regions of myelin decompaction (A, arrows; B, purple) at the
indicated months (mo) post-tamoxifen treatment. Insets: regions from dotted rectangles (50,0003). Number of myelin wraps (triangles) in WT and pNf1f/f mutants
are shown in (B).
(C) The percent of decompacted fibers among total fibers and number of quadrants with decompaction (color code) in the short-term (ST; 1 month) and long-term
(LT; 6–10 months) post-tamoxifen is shown. Significantly increased decompaction is found in pNf1f/f mice at ST (n = 5 mice,**p < 0.01), and in pNf1f/+ mice at LT
(n = 3 mice,*p < 0.05), as compared to WT (ST-LT, n = 6 mice). Moderate (1–3 quadrants), but not significant (ns), decompaction is observed in pNf1f/+ mice at ST

(legend continued on next page)
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signaling (Ratner and Miller, 2015). RAS and Notch pathways can
cooperate or antagonize each other in a context-dependent
manner. Although Notch acts downstream of Nf1 during differentiation of neural stem cells (Chen et al., 2015), no links between
these pathways have been described in mOL. Here, we show genetic and pharmacological evidence indicating that Notch
signaling controls progressive and Nf1 gene-dose-dependent
myelin defects in the corpus callosum (CC) of PlpCreER;Nf1flox
animals. Abnormal behavior in hemizygous mutants is rescued
by pharmacological inhibition of Notch. Mechanistically, aberrant Notch activation and myelin defects are rescued by inhibition of NO signaling, revealing NO as a crucial link between
RAS and Notch pathways. Increased activation of Notch is
also found in Nf1+/ mice and in WM of NF1 patients, suggesting
that abnormal Notch signaling is a feature of NF1.
RESULTS
Nf1 Loss in mOLs Causes Nf1 Gene-Dose-Dependent
Progressive Myelin Decompaction
We previously reported that myelin decompaction occurs in the
optic nerve (ON) 6–12 months after tamoxifen-induced deletion
of Nf1 in Plp1-expressing mOLs (Mayes et al., 2013). To study
whether Nf1 loss-dependent myelin defects occur in the brain
and their progression, we analyzed the CC of adult tamoxifentreated homozygous (PlpCreER;Nf1flox/flox, henceforth pNf1f/f)
and hemizygous (PlpCreER;Nf1flox/+, henceforth pNf1f/+) Nf1
mutant mice and wild-type (WT) animals (Nf1flox or PlpCreER), using electron microscopy (Figures 1A and 1B). Unbiased counting
of myelinated axons showed no significant differences in g-ratio
of control animals between 1 and 8 months after tamoxifen treatment (Figures S1A and S1C). Significantly decreased g-ratio in
Nf1 hemizygous mutants, as compared to WTs, was detected
at 1 month with a further decrease 6 months post-tamoxifen,
indicating progressive changes in fiber structure. In contrast, in
homozygous Nf1 mutants, decreased g-ratio occurred within
1 month post-tamoxifen, and showed slight but significant recovery by 6 months post-tamoxifen (Figures S1A and S1C). At
this time point, the density of EGFP reporter-positive recombined cells did not differ between WT and Nf1 mutants (Figures
S1F and S1G). Although Nf1 may recombine with different efficiency than EGFP, this result suggests that the trend toward recovery is not due to a depletion of mutant cells. Both parameters
determining g-ratio were affected by Nf1 loss in mOLs; pNf1 mutants showed increased myelin thickness due to decompaction
at intraperiod lines (number of myelin lamellae remained unchanged, Figures 1B and S1B) and decreased axon diameter
(Figure S1E). The latter is likely secondary to disturbed myelin
integrity (Cole et al., 1994; Colello et al., 1994), because neurons

with axons in the CC do not express the PlpCre allele (Koenning
et al., 2012; Mayes et al., 2013).
Regions of decompacted myelin were evident in hemizygous
and homozygous pNf1 mutants 1 month post-tamoxifen, albeit
to different extents (Figures 1A, insets, and 1B). Decompacted
fibers among total fibers were quantified. Additionally, severity
of decompaction was reflected by the number of quadrants
around each axon showing decompaction (Figure 1C, color
code). Control animals show baseline myelin ‘‘decompaction’’
(Figure 1C, 1–2 quadrants) in the short- (ST, 1 month) and
long-term (LT, 6–9 months) post-tamoxifen treatment, likely indicating cross-sections through paranodal loops and SchmidtLanterman incisures. One month post-tamoxifen, pNf1f/+ mutants show decompaction in 1–3 quadrants, but not significant
total decompaction, while pNf1f/f show significantly increased
total decompacted fibers in 1–4 quadrants, as compared to
WTs. Confirming a progressive phenotype, by 6–8 months
post-tamoxifen significantly increased decompaction was also
detected in hemizygous mice (Figure 1C). Thus, myelin decompaction in the CC is Nf1 gene-dose-dependent and progressive.
Nf1 Regulates Myelin Compaction through RAS-MAPK
Pathway Activation
To define the mechanisms responsible for myelin decompaction
in the CC of Nf1 mutants, we first analyzed RAS/MAPK pathway
activation, which results in phosphorylation and activation of
ERK1/2 (pERK). The WT CC showed pERK immunostaining in
rare, mainly CC1 cells (Figure 1D). Consistent with activation
of MAPK signaling in Nf1 mutants, increased faint pERK signals
were observed in CC1+ mOLs of pNf1f/+ mice and strong pERK
signals in pNf1f/f mice, at time points when severe decompaction is observable. Quantitative analysis confirmed significantly
increased pERK+;CC1+ mOLs in pNf1f/f mice 1 month posttamoxifen, as compared to controls, while a trend toward increase was detected in pNf1f/+ mice (Figure 1E). Other signal
pathways could cause myelin decompaction in pNf1f/+ mutants,
and/or modestly increased pERK could cause decompaction in
the long-term; if so, decompaction should be sensitive to inhibition of MEK, the ERK kinase. At 9 months post-tamoxifen when
myelin decompaction is detectable, we treated Nf1 hemizygous
mutants for 21 days with PD0325901, a brain penetrant MEK
inhibitor (MEKi, 1.5 mg/kg). At this therapeutically relevant
dose (Barrett et al., 2008), MEKi fully rescued myelin decompaction (Figure 1C) and g-ratio (Figure S1D) in pNf1f/+ mice.
In fact, myelin was more compacted than WTs, suggesting
that basal MAPK signaling contributes to the maintenance of
normal compact myelin structure. In homozygous Nf1 mutants,
MEKi improved the severity of decompaction (quadrants) and
significantly increased g-ratio, but failed to fully rescue these

(n = 3 mice). MEKi treatment rescues decompaction in pNf1f/+ mutants (n = 3 mice, *p < 0.05) but does not change decompaction in pNf1f/f mutants (n = 3 mice).
Data are presented as the mean + SEM. One-way ANOVA; p = 0.0005, and Tukey’s multiple comparisons test.
(D) Immunostaining of pERK (red) and CC1 (white) in the CC of the indicated genotypes. Magnifications of squared regions (left) depict a pERK+;CC1 cell in
WT (nuclear signal, arrowhead), pERK+(faint);CC1+ mOLs (yellow arrows) in pNf1f/+, and pERK+(strong);CC1+ mOLs in pNf1f/f mice. LV, lateral ventricle. Scale
bar, 10 mm.
(E) Significantly increased pERK+;CC1+/total CC1+ mOLs are found in pNf1f/f mice as compared to WT (n = 4 mice/genotype, t test;**p = 0.0053, data are the
mean + SEM).
See also Figures S1 and S2.
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parameters (Figures 1C and S1D), perhaps because the treatment did not abolish abnormal MAPK signaling. In support of
this hypothesis, while MEKi significantly decreased pERK+;CC1+
mOLs, they remained significantly increased in pNf1f/f mice as
compared to controls (Figures S2A and S2B). Thus, MAPK
signaling contributes to the aberrant myelin compaction in Nf1
mutants, but a clinically relevant dose of MEKi is insufficient to
rescue cells with complete Nf1 loss of function.
Nf1 Loss Increases Notch Pathway Activity in Glial Cells
In Vitro and In Vivo
As in a previous study (Mayes et al., 2013), WT and mutants
showed similar MBP expression around CC1+ cells (Figure S2C).
We aimed to identify other molecules/pathways downstream
ERK activation that influence cell signaling and myelin defects
following Nf1 loss. We postulated that transcriptional changes
might underlie Nf1-loss effects, as MAPK signaling regulate
gene expression (Ishii et al., 2014). Using microarray gene
expression analysis of glia-enriched cultures (Bennett et al.,
2003), we identified genes with significantly altered expression
in Nf1 / as compared to WT cultures. Interestingly, Hes5, a
direct transcriptional target of canonical Notch signaling, was
the most upregulated gene in Nf1 mutant cells, and other
Notch-related genes (Dll1 and Dll3) were also significantly
increased, as validated by qRT-PCR (Figure 2A). Upon ligand
binding, a cleaved Notch intracellular domain (NICD) is generated, correlating with Notch activation. NICD detection by western blot increased in Nf1 / as compared to WT cultures
(Figure 2B). To verify these results in vivo in an OL-enriched population, we performed RNA sequencing (RNA-seq) transcriptome analysis using WT and pNf1f/f optic nerves, 1 month
post-tamoxifen. We identified significant increases in transcripts
encoding the Notch targets Hes5, Cntnap2, and Cttnbp2 (MeierStiegen et al., 2010). Transcripts encoding Notch ligands also
increased (Dll1, Dlk2, Dner, and Cntn1) or decreased (Thbs1,
Postn, and Jag1). Transcripts encoding GJ and TJ proteins expressed in the oligodendrocyte-lineage, including Claudin 11,
were also significantly decreased (Figure 2C). To test whether
loss of Nf1 in mOLs increases Notch activation in vivo, we
analyzed Nf1 mutants carrying the transgene Hes5GFP, a re-

porter of canonical Notch pathway activation that is not expressed significantly in normal mOLs. WT animals and Nf1 mutants contained, as expected, Hes5GFP+;GFAP+ astrocytes
(Figure S3A) and rare Hes5GFP+;CC1+ mOLs in the CC (Figure 2D, insets). Although Hes5GFP+ mOLs were significantly
increased in pNf1f/f animals as compared to WT animals (Figures 2E and S4E), they accounted for only 1.41% ± 0.20% of
CC1+ cells in the CC, and Hes5GFP signal did not overlap with
pERK+CC1+ mOLs (Figure S3B).
Hes5 is one of many Notch effectors. To test whether other
Notch effectors are likely to be activated in mOLs after loss of
Nf1, we analyzed NICD immunoreactivity using a specific antibody (aNOTCH). WT mice showed aNOTCH cytoplasmic signals
in rare CC1+ mOLs. Significantly increased numbers of
aNOTCH+(nuclear);CC1+ mOLs were detected in pNf1f/f animals
(Figures 2D and 2F), corroborating Nf1 loss-driven, abnormal,
Notch activation. Interestingly, aNOTCH signals were detected
in recombinant and non-recombinant cells (Figure S3C), supporting the idea that cell autonomous and non-cell-autonomous
effects occur downstream of Nf1 mutation in mOLs (Mayes et al.,
2013).
Activation of Notch in mOLs Reduces Claudin
11 Expression and Causes Myelin Decompaction
We investigated whether abnormal Notch activation in mOLs is
sufficient to disrupt myelin compaction. We genetically activated
Notch signaling in mOLs with the tamoxifen-inducible RosaNICD
allele driven by PlpCreER (pNICD). One month post-tamoxifen
treatment, myelin decompaction (Figure 2G) and decreased
g-ratio (Figure S4A) were found in pNICD animals, as compared
to WTs. Decreased Claudin 11 corelates with myelin decompaction in pNf1 mutants (Mayes et al., 2013), and WB analysis
showed a significant decrease of this TJ protein in the forebrain
of pNICD mice (Figure S4B). Thus, genetic activation of Notch in
mOLs mimics phenotypes caused by Nf1 loss.
Notch Genetic Inhibition Rescues Myelin Decompaction
in Nf1 Mutants
RBPJ is a transcriptional co-factor required for canonical Notch
signaling. To test whether increased canonical Notch signaling

Figure 2. Increased Notch Pathway Activity in mOLs Causes Myelin Decompaction in pNf1 Mutants
(A) Data from microarray analysis and qRT-PCR valida tion show increased expression of genes in Nf1 / glial-enriched cultures (t test, Hes5****p < 0.0001;
Dll1**p = 0.0055, Dll3**p = 0.004, n = 3 cultures).
(B) Western blot analysis of Notch1 and Ras10 (loading control) indicates increased activated Notch 1 (97 kD) in Nf1 / glia-enriched cultures.
(C) RNA-seq analysis of pNf1f/f ON 1 month post-tamoxifen. Heatmap showing gene expression levels (log2 fold change) and p values for genes of canonical and
non-canonical Notch ligands (Dll1, Dlk2, Dner, Cntn1, Thbs2, Postn, Jag1), Notch targets (Hes5, Cntnap2, Cttnbp2, Spi1), tight junctions (Cldn11, Tjp2), and GAP
junctions (Gjb6, Gjb2). Expression of Mbp, Plp1, Mag, Mog, and Omg did not show significant changes (n = 3/genotype, DESeq normalization method).
(D) Immunofluorescence of Hes5GFP (green), aNOTCH (red), and CC1 (white) 1 month post-tamoxifen. In magnification (right) of squared regions: Hes5GFP
(yellow arrows) is detected in rare CC1+ (weak) mOLs, aNOTCH (arrowheads) is detected in cytoplasm of mOLs in WT (Hes5GFP) and nuclei of abundant mOLs in
pNf1f/f;Hes5GFP mutant (pink, bottom/right). CC, corpus callosum; LV, lateral ventricle. Scale bar, 10 mm.
(E) The percent of Hes5GFP+;CC1+/CC1+ cells significantly increases in pNf1f/f mutants as compared to WT (n = 4 mice/genotype, t test; **p = 0.0013). Inset:
y axis enlargement.
(F) The percent of aNOTCH+;CC1+/CC1+ cells significantly increases in pNf1f/f mutants (n = 7 mice) as compared to WT (n = 4 mice, t test; ***p = 0.001). Data are
the mean + SEM.
(G and H) Percent of decompacted fibers and severity of decompaction (quadrants) in the indicated genotypes in the short- (1 month) or long-term (6–9 months)
post-tamoxifen. Increased decompaction is shown in PlpCre;RosaNICD (G, n = 4 mice, t test, ***p < 0.0001), and pRbpjf/f (H, n = 3 mice, *p < 0.01) as compared to
WTs (n = 6 mice). Note that decompaction is not rescued in pNf1f/f;Rbpjf/f (versus pNf1f/f), but it is rescued by additional treatment with MEKi (n = 3, **p < 0.001,
one-way ANOVA). Decompaction is fully rescued in pNf1f/+;Rbpjf/f mutants (versus pNf1 f/+, n = 3 mice /genotype, *p < 0.01 one-way ANOVA).
Error bars show ± SEM. See also Figures S3 and S4.
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Figure 3. Pharmacological Inhibition of
Notch Activation in pNf1 Mutants Rescues
Decompaction and Aberrant Behavior
(A) Number of Hes5GFP+ cells in the CC of vehicletreated (n = 5 mice) or gamma secretase inhibitor (GSI)-treated (n = 12 mice) WT mice (t test,
*p = 0.0001).
(B) The percent of decompacted fibers and
quadrants with decompaction does not change
after GSI treatment in WT animals (n = 6 vehicletreated, n = 4 GSI-treated animals, t test, ns, p =
0.4516) and pNf1f/f mutants (n = 5 mice/genotype,
ns, p = 0.2768). Decompaction is rescued in pNf1f/
+ mice treated with GSI (n = 4 mice, t test,
**p = 0.0019) as compared to vehicle-treated
pNf1f/+ (n = 3). ST, 1 month post-tamoxifen;
LT, 6–10 months post-tamoxifen.
(C and D) Evaluation of the acoustic startle
response. (C) pNf1f/+ mutant mice (n = 21 mice)
present increased Vmax to the acoustic startle
response following the 73 dB, 77 dB, and 82 dB
pre-pulse stimuli, as compared to WT mice (n = 19
mice, two-way ANOVA, F[4,152] = 3.05, *p < 0.05).
(D) The heightened startle response in pNf1f/+
mutants is abolished after treatment with GSI
MRK-003, as no significant difference in Vmax is
observed between WT (n = 21 mice) and pNf1
mutants (n = 19 mice, two-way ANOVA, F[4,152] =
2.73).
Error bars show ± SEM. See also Figure S4.

regulates phenotypes in Nf1 mutants, we genetically inactivated
Notch signaling in mOLs using PlpCreER;Nf1fl/+(or Nf1fl/f);Rbpjfl/fl
mice, in which Rbpj and Nf1 are inactivated upon tamoxifen
treatment. Unexpectedly, homozygous Rbpj inactivation in
mOLs (pRbpjf/f) caused myelin decompaction 1 month posttamoxifen treatment (Figure 2H). Thus, imbalance in Notch
signaling and/or compensatory responses affect myelin
compaction in this genetic model. Importantly, hemizygous Nf1
mutants with deletion of Rbpj (pNf1f/+;Rbpjf/f) showed full
rescue of myelin decompaction (Figure 2H) and g-ratio (Figure S4C) 6–8 months post-tamoxifen. Inactivation of Rbpj in
Nf1 homozygotes rescued g-ratio but did not significantly impact
myelin decompaction 1 month post-tamoxifen; however, additional treatment of pNf1f/f;Rbpjf/f mice with MEKi fully rescued
compaction to WT levels (Figure 2H). Overall, these data indicate
that Notch signaling is crucial for the maintenance of myelin
structure in the WT setting and in the context of Nf1 loss.
Gamma Secretase Inhibition Rescues Myelin Defects
and Aberrant Behavior in Nf1 Mutants
To test whether Nf1 loss-driven phenotypes can be rescued by
pharmacological inhibition of Notch we used the blood-brain
barrier-permeable gamma secretase inhibitor (GSI) MRK-003
(Chu et al., 2013). GSI administration to WT animals (weekly for
3 weeks) significantly decreased the number of Hes5GFP+ cells
in the CC, confirming drug efficacy (Figure 3A). Importantly, GSI
treatment had no effect on myelin compaction in WT animals. In
contrast, GSI treatment rescued decompaction (Figure 3B) and
g-ratio (Figure S4D) in pNf1f/+ animals 6–10 months posttamoxifen. In fact, myelin compaction increased over WT levels,
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similar to the effect of MEKi (Figure 1C). In Nf1 homozygous mutants GSI significantly increased g-ratio (Figure S4D), however,
no significant changes in myelin decompaction were observed.
These data suggest that GSI treatment normalizes the unbalanced Notch signaling that promotes decompaction in Nf1
mutants.
NF1 patients display mutation/loss of 1 NF1 allele and present
locomotor, cognitive and attention issues. We therefore tested
whether behavior is altered in hemizygous pNf1 mutants. We
evaluated sensory gating deficits in Nf1 hemizygous mutant
mice (C57BL/6 genetic background), by analyzing the prepulse
inhibition of startle response (Vorhees et al., 2011), 9 months
post-tamoxifen treatment. Significantly heightened response to
startle at 73–82 dB, was found in pNf1 mutants as compared
to controls (Figure 3C). Remarkably, all increased startle responses (73–82 dB) were blocked by treatment with GSI for
3 weeks, as compared to littermate WTs (Figure 3D). Thus, hemizygous Nf1 mutation in mOLs causes myelin structural defects
and behavioral abnormalities that can be rescued by pharmacological inhibition of Notch signaling.
Notch Activation and Myelin Decompaction Are Due to
Increased Nitric Oxide Signaling in Nf1 Mutants
Nf1 loss in oligodendrocytes was reported to result in increased
reactive oxygen/nitrogen species in the forebrain, and treatment
with the antioxidant N-acetyl cysteine rescued cell-autonomous
and non-cell-autonomous defects in the ON of pNf1 mutants
(Mayes et al., 2013). To test whether mOL NO contributes to
CC myelin abnormalities, Nf1 mutants were treated with a specific inhibitor of NO synthases L-NAME (N-nitroarginine methyl

Figure 4. NO Controls Notch Activation and
Concomitant Inhibition of Notch/NO or
NO/MAPK Signaling Rescues Decompaction in pNf1f/f Mutants
(A) Decompacted fibers (%) and quadrants with
decompaction in mice treated with L-NAME
(7 days) and MEKi (21 days). L-NAME treatment
rescues myelin compaction in the long-term (LT)
pNf1f/+ mice (n = 4 mice/treatment, **p < 0.01).
Note that % of decompacted fibers does not
significantly change in L-NAME-treated pNf1f/f
mice (ST, short-term), but decompaction is fully
rescued in L-NAME-treated pNf1f/f;Rbpjf/f (n = 3
mice, *p < 0.05), or in L-NAME;MEKi-treated
pNf1f/f (n = 3 mice, **p < 0.01), as compared to
pNf1f/f mice.
(B) Immunostaining of aNOTCH (red) and CC1
(white) in the CC of vehicle- or L-NAME-treated
WTs and pNf1f/f mutants. Note the lower number
of aNOTCH+;CC1+ cells in L-NAME-treated
pNf1f/f mutants, as compared to untreated
mutants. Scale bar, 10 mm.
(C) WT and pNf1f/f mice show no significantly
different numbers of aNOTCH+;CC1+ mOLs (yellow arrows in B) after L-NAME treatment (n = 3
mice/genotype, t test, p = 0.9721). Untreated animals (from Figure 2F) are shown for comparison.
(D) Flow cytometry analysis of forebrain cells
indicates that the number of GalC+ mOLs
showing NO signals does not change in
PlpCreER;RosaNICD (pNICD) mice, as compared
to WT animals (n = 3 mice/genotype, t test,
p = 0.86).
(E) Flow cytometry analysis of forebrain cells indicates that the number of GalC+ mOLs showing
NO signals does not change in pNf1f/f;pRbpjf/f
mice as compared to pNf1f/f mutants (n = 3 mice/
genotype, t test, p = 0.29).
Error bars show ± SEM. See also Figure S4.

ester, 0.4 mg/kg) for 7 days, starting after severe decompaction
is detectable. L-NAME treatment fully rescued myelin compaction (Figure 4A) and g-ratio (Figure S4F) in pNf1f/+ mutants. In
pNf1f/f mice, treatment significantly increased g-ratio, but did
not rescue compaction to WT levels. Notably, full rescue of decompaction in the homozygous mutants required inhibiting
both Notch and NO signaling (Rbpj deletion and L-NAME treatment) or MAPK and NO signaling (MEKi and L-NAME treatment)
(Figures 4A and S4F).
We therefore tested whether elevated NO levels drive Notch
activation (Charles et al., 2010; Jeon et al., 2014) in Nf1 mutants
or whether Notch activation is an independent Nf1-driven signal
in mOLs. L-NAME treatment for 7 days rescued the abnormally
increased number of aNotch+;CC1+/CC1+ mOLs in the CC of
pNf1f/f mutants, as compared to L-NAME-treated WT mice (Figures 4B and 4C). Thus, abnormally increased Notch signaling in
mOL is reduced by NOS inhibition. Flow cytometry analysis of
forebrain showed that neither NO nor superoxide signals
changed in Hes5GFP+ cells of pNf1f/f mutants, versus Hes5+
cells in WT animals (Figure S4E). Demonstrating that Notch

does not drive NO, overexpression of NICD in mOLs
(PlpCreER;RosaNICD) did not alter numbers of NO+GalC+ cells,
and NO+ cells remained unchanged in Nf1 mutants with genetic
inactivation of canonical Notch signaling as compared to pNf1f/f
mutants (Figures 4D and 4E). A linear MAPK/NO/Notch pathway
downstream Nf1 loss might explain why single agent treatments
fully rescue myelin decompaction in hemizygous pNf1 mutants.
However, combined inhibition of MAPK, NO, and Notch
signaling (Figures 2H and 4A) is necessary to normalize effects
in homozygous mutants plausibly because of a more robust
pathway activation; durable feedback loops may also explain
this finding.
Nf1 Loss and Oligodendrocyte Numbers
Nf1 loss in mOLs was found to increase numbers of Olig2+
cells in the CC 4 days after tamoxifen treatment (Mayes
et al., 2013). To test if this increase is durable, we quantified
CC Olig2+ cells 1 month post-tamoxifen. Olig2+ cells were
not significantly increased in pNf1f/f mutants versus WT (Figures S6A and S6B). As Olig2 labels all oligodendrocyte lineage
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Figure 5. Notch Signaling Increases in Nf1+/ mice, and aNotch+ Cells Are Increased in NF1 Patient WM
(A and B) The number of Hes5GFP+ cells in the CC (A) of Nf1+/ mice is significantly increased (B), as compared to WT animals (n = 3 mice/genotype, t test,
***p = 0.0004).
(C) Immunodetection of NICD (aNOTCH) with a specific antibody (Cell Signaling, cs2421) in the subcortical WM (scWM) of NF1 patient brains (n = 2) and normal
human brains (n = 2). Representative aNOTCH nuclear signals are shown with red arrows (insets). Scale bars, 50 mm.
(D) Quantification of total aNOTCH+ cells per 203 field suggests increased Notch activity in the scWM of NF1 patients, as compared to normal brain (n = 2 NF1
patients, n = 2 normal brains, 2 technical replicates/condition, t test, **p = 0.0042).
(E) Quantification of aNOTCH+ cells as percent of total cells per 203 field supports increased Notch activity in the scWM of NF1 patients, as compared to normal
brain (n = 2 NF1 patients, n = 2 normal brains, 2 technical replicates/condition, t test, ***p = 0.0014). Error and significance of the graphs reflect only experimental
variability.
Error bars show ± SEM. See also Figure S5.

cells, we identified by flow cytometry-specific forebrain cell
populations using the markers PDGFRa, O4, and GalC.
mOLs (PDGFRa GalC+ or O4 GalC+) did not show altered
numbers in pNf1 mutants. Therefore, overall changes in
numbers of oligodendrocytes are unlikely to account for our
findings. We note that maturing OLs (PDGFRa+GalC+) were
significantly increased in pNf1f/f animals (Figure S6C), and
within the Hes5+ population, O4+GalC+ cells were also significantly increased (Figure S6D). Non-cell-autonomous effects on
oligodendrocyte progenitors and/or re-expression of immature
OL markers in GalC+ mOL might explain these phenotypes.
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Nf1+/ Mice Show Increased Notch Activity, and NF1
Patients Show Hyperactivated Notch
To determine whether control of myelin compaction through
Notch signaling might be relevant to NF1 patients, we first
evaluated Notch activation in the brain of Nf1+/ mice, which
mimic NF1 patients genotype with germline mutation in
one Nf1 allele in all brain cells. Notch activation was elevated
in Nf1+/ mutants, as in the Notch-activity reporter mouse
Nf1+/ ;Hes5GFP, numbers of Hes5GFP+ cells in CC were
significantly increased, as compared to WT animals (Figures
5A and 5B).

Finally, we used two antibodies to detect cells with activated
Notch+ (aNOTCH or NICD) in brain sections from previously
described adult NF1 patients (Nordlund et al., 1995). Both antibodies (ab8925 and cs2421) detected higher number of NICD+
cells in the subcortical WM of NF1 patients (n = 2), as compared
to normal adult brain (n = 2) (Figures 5C and S5A). Quantification
of two technical replicates (reflecting experimental variability, not
the variability of the biological process), showed significantly
increased number of aNOTCH+ cells (Figure 5D). To address
the issue of precisely matching brain regions in the limited specimens available, we normalized the percentage of aNOTCH+
cells to the total number of cells per field and found similar results
(Figure 5E). Overall, our data are consistent with the idea that
abnormal Notch signaling downstream of Nf1 loss and NO increase contribute to NF1 patient pathology.
DISCUSSION
The study of WM abnormalities that correlate with motor, sensory, or cognitive changes in pathological situations may help
to identify mechanisms relevant to normal brain function. We
focused on brain pathology in NF1, a common genetic disorder
in which patients show WM disorganization on brain imaging,
and neurological deficits. We show that Notch signaling, along
with MAPK and NO, are aberrantly activated after Nf1 loss in
mature oligodendrocytes, causing myelin decompaction and
changing animal behavior.
Patient mutations in genes throughout the RAS-MAPK
pathway (Rasopathy genes) compromise brain function (Rauen,
2013). Nf1 is a well-studied Rasopathy gene that acts as a regulator of RAS-MAPK signaling (Donovan et al., 2002; Ratner and
Miller, 2015). Increasing evidence confirms a role for MAPK activation in NF1 brain. For example, abnormally enlarged CC resulting from Nf1 loss is rescued by perinatal MEK inhibition (Wang
et al., 2012). In oligodendrocyte progenitors with Nf1 mutation,
basal and FGF-stimulated RAS-GTP are increased, proliferation
increases, and differentiation is aberrant, although myelination
occurs (Bennett et al., 2003). In contrast to these developmental
studies, our analyses ensue after deletion of Nf1 in mature cells.
Our results are encouraging as they support the idea that alterations in NF1 brain may be susceptible both to prevention and
to therapy.
Myelin decompaction resulting from Nf1 loss in oligodendrocytes accounts for pathological increases in myelin thickness,
as numbers of myelin lamellae did not significantly change.
This result differs from studies in which the RAS effector proteins ERK1/2 regulate myelin thickness by increasing numbers
of myelin wraps (Ishii et al., 2013), as assessed using gain and
loss-of-function models. In our model, after Nf1 loss, RAS,
MEK, and ERK proteins are present at normal levels; therefore,
extrinsic stimuli activate transient signaling through MEK/ERK.
The transience of the RAS signal after Nf1 loss likely accounts
for the discrepancy with studies of constitutive activation or
complete loss of ERK. Other RAS effector pathways activated
by loss of Nf1 may also contribute to decompaction after
homozygous Nf1 loss, although this seems less likely given
that MEK inhibition alone blocks decompaction after hemizygous Nf1 loss.

Increased Notch signaling following Nf1 loss was demonstrated by microarray/RNA-seq analyses and corroborated by
in vivo detection of NICD in CC1+ mOLs. Cell-autonomous roles
of oligodendrocyte Notch in controlling myelin compaction are
supported by our genetic gain- (NICD) and loss-of-function
(Rbpj) models. Furthermore, although GSI can have effects on
other substrates, our finding that GSI rescues aberrant myelin
decompaction is consistent with our detection of active nuclear
NICD in oligodendrocytes and the genetic data indicating that
Notch blockade via Rbpj loss reverses effects of Nf1 loss.
The correlation between rescued decompaction and GSI
rescue of abnormal startle response in pNf1 mutants suggests
that myelin compaction is relevant to normal behavior. Importantly, GSI treatment did not affect WT myelin structure or
behavior in our study. It will be of great interest to define a direct
link between abnormal activation of Notch with decompaction
and behavior in animal models and whether increased activation of Notch in NF1 patients is linked to their neurological
issues.
Notch, via Hes5, regulates many processes in immature oligodendrocyte lineage cells (Liu et al., 2006; Watkins et al., 2008).
We found that Hes5 transcript is increased in a Nf1 mutant glial
precursor-enriched population in vitro, and NICD and Hes1/5
increases were recently reported downstream of Nf1 inactivation in neural stem cells (Chen et al., 2015). However, it is likely
that Notch effector-driven cell-autonomous effects on mOL do
not require Hes5, in that CC1+Hes5+ are rare (albeit increased)
in Nf1 mutants and do not show detectable ERK activation.
It remains possible that in Nf1 mutants, Hes5+ cells and/or an
increased population of O4+GalC+ maturing oligodendrocytes,
contribute to abnormal myelin compaction. However, the broad
expression of mOL NotchICD in the absence of Hes5 strongly
suggests the pathological relevance of alternate Notch effector
proteins in this setting.
We previously reported that Nf1 mutation in oligodendrocytes
causes small but significant increase in NO levels in the forebrain
(Mayes et al., 2013). Here, we extend the results to CC oligodendrocytes and demonstrate that increased NO is upstream
of Notch-mediated myelin decompaction. In oligodendrocytes,
NO is protective at low levels, while at high levels causes
ERK1/2-mediated toxicity (Li et al., 2011) and downregulation
of myelin genes preceding cell death (Jana and Pahan,
2013). Also at low concentrations, NO induces cGMP-mediated morphological changes (Garthwaite et al., 2015). As no
increased mOL cell death was found in pNf1 mice (Mayes
et al., 2013), it is probable that NO does not accumulate to lethal
levels after Nf1 loss. Yet, myelin structural defects develop in an
Nf1 gene-dose-dependent manner. We propose that the slow
progression of myelin decompaction in hemizygous Nf1 mutants is caused by modest increased MAPK and downstream
signals that causes cumulative damage, while biallelic loss of
Nf1 causes higher levels of pathway activation and more rapid
decompaction. Other Nf1 gene-dose-dependent phenotypes
have been reported. For example, Nf1 hemizygous oligodendrocyte precursors are expanded in vitro, to a lesser extent
than Nf1 homozygous mutant cells (Bennett et al., 2003). Only
Nf1 / sympathetic neurons develop neurites independent of
growth factor (Vogel et al., 1995), but Nf1+/ mice show defects
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in Morris water maze tests and dopamine-based learning (Anastasaki et al., 2015).
It is well known that RAS-GTP signaling can act up or downstream of Notch and have a cooperative or antagonistic outcomes (Sundaram, 2005). In fact, multilineage differentiation of
neural stem cells is controlled by Nf1 via RAF/MEK pathway
and Notch activation (Chen et al., 2015), however, the link between these signal pathways is unclear. We find that increased
active Notch is rescued by L-NAME treatment, suggesting that
NO is a mediator between RAS-Nocth signaling in Nf1 mutants.
Thus, a linear MAPK/NO/Notch pathway might drive myelin decompaction and behavioral phenotypes in hemizygous mutants
(Figure 6A). In support of this idea, single agent treatment with
MEKi (Figure 1C), GSI (Figure 3B), or L-NAME (Figure 4A) fully
rescue myelin decompaction, and GSI alone rescues behavioral
abnormalities. Similar pathway interactions have been reported
in PDGF-induced gliomas, in which NO/cGMP/PKG (Charles
et al., 2010) or NO/ID4/Jagged1 (Jeon et al., 2014) signaling drive
Notch activation and tumor growth.
A linear MAPK/NO/Notch pathway, however, does not easily
explain why blocking each pathway alone does not rescue
decompaction in homozygous mutants. A parsimonious explanation is that the more robust activation of RAS in pNf1f/f
mutants requires longer treatments with single drugs, higher
doses, or combinations of drugs, to fully diminish the effects
of RAS over activation (Figure 6B). Alternatively, increased
MAPK, NO, and Notch signaling might cause durable transcriptional or posttranscriptional changes that feedback and potentiate the effects of the entire pathway. In support of this idea,
NOS1-3 proteins are increased in pNf1 homozygous mutants
(Mayes et al., 2013). Given that oligodendrocytes express
NOS1 (Yao et al., 2012) and possibly NOS2 (Boullerne and Benjamins, 2006), transcriptional regulation of these and other genes
involved in the pathway is conceivable. The specific Notch effector(s) controlling myelin compaction remain unknown. Myelin
proteins regulating compaction, including Claudin 11, might be
involved. We found that genetic activation of Notch decreases
Claudin 11. Of note, mice with loss of the Plp1 and Cldn11
show impaired motor behavior and myelin decompaction, similar
to those found in pNf1 mutants (Chow et al., 2005). Regulation of
Cldn11 by Notch has not been reported, and in silico analysis do
not show binding sites for CSL/Rbpj (http://genome.ucsc.edu).
However, a binding site for PU.1, a transcription factor regulated by Notch (Chen et al., 2008) and downregulated in pNf1
mutants, is upstream of Cldn11. Additional downregulation of
TJ/GJ genes (Tjp2, Gjb6, Gjb2) may also contribute to abnormal
myelin and behavior (Figure 6).
Most myelinated fibers in Nf1 mutants showed decompaction,
even though deletion of Nf1 occurs in a smaller number of mOLs
(Koenning et al., 2012; Mayes et al., 2013). This result suggests
that a diffusible messenger signals to non-recombinant cells.
Diverse paracrine roles of NO have been widely reported in the
brain (Calabrese et al., 2007), thus, NO could mediate effects
to neighbor cells in pNf1 mutants (Figure 6). In fact, several
non-cell-autonomous defects are detected after deletion of Nf1
in mOLs (Mayes et al., 2013).
In summary, activation of Notch signaling, downstream of
MAPK and NO, results in myelin decompaction and behavioral
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changes in Nf1 hemizygous mutants. It is believed that most
cells in NF1 patient brains contain one normal NF1 allele and
one mutant/lost allele of the NF1 gene. However, there are brain
regions with especially poor organization that may represent
regions of biallelic NF1 loss, based on DTI (Ferraz-Filho et al.,
2012). If biallelic NF1 mutations are present in oligodendrocytes
in NF1 patient brains and cause WM alteration (Ferraz-Filho
et al., 2012; Karlsgodt et al., 2012), drug combinations might
be needed therapeutically. Importantly, our findings that NO/
Notch signaling is perturbed in Nf1+/ mice, and that NICD
increases in NF1 patients raise the intriguing possibility that
the pathways we identified in mouse mOLs will be relevant to
NF1 patients. Based on these studies, drugs that block the Nf1
loss-dependent increased NO and subsequent Notch activation
should be considered to treat disease manifestations in NF1.
EXPERIMENTAL PROCEDURES
Mouse Strains
All mouse studies were approved by the Cincinnati Children’s Hospital
Research Foundation Institutional Animal Care and Use Review Committee
(IACUC). The generation and genotyping of mice carrying Nf1fl/fl [Nf1tm1Par/J]
(Zhu et al., 2002), PlpCre [B6.Cg-Tg(Plp1-Cre/ERT)3Pop/J] (Doerflinger et al.,
2003), Hes5-GFP [Tg1(Hes5GFP)Gsat/Mmmh] (Gong et al., 2003), Rbpjfl/fl
[RBP-Jf/f] (Han et al., 2002), RosaNICD [Gt(ROSA)26Sortm1(Notch1)DAM/J]
(Murtaugh et al., 2003), and Nf1+/ (Brannan et al., 1994) alleles, are described
in previous studies. Mice were maintained on the C57BL/6 background. For
behavioral studies, only adult female mice were used. In all other studies,
we used adult mice of both sexes. Mice were housed in a temperature- and
humidity-controlled vivarium on a 12 hr light-dark cycle with free access to
food and water.
Pre-clinical Therapeutics
Gamma secretase inhibitor (GSI,MRK-003; Merck) was made fresh weekly
and dosed at 300 mg/kg in 0.5% methocel by oral gavage (Lewis et al.,
2007; Sparey et al., 2005). For pathology, we dosed mice once weekly for
4 weeks and sacrificed 6 hr after the last dose (n = 5 doses). For flow analysis,
we dosed mice once weekly for 1 week and sacrificed mice 6 hr after the last
dose (n = 2 doses). Fresh solution of L-NAME (L-NG-nitroarginine methyl ester,
100 mM in 13 PBS; Sigma-Aldrich) was administered daily at 0.4 mg/kg.
For pathology and flow analysis, mice were injected intraperitoneally (i.p.)
daily for 7 days and sacrificed 6 hr after the last dose. MEK inhibitor
(PD0325901; Pfizer) was made fresh weekly and dosed at 1.5 mg/kg/day in
0.5% methocel/0.2% Tween 80, by oral gavage. For pathology, we dosed
mice every day for 3 weeks. For flow analysis, we dosed mice every day for
7 days and sacrificed 6 hr after the last dose.
Behavior
Behavioral assessments were completed on pNf1fl/+ mice (F12, backcrossed
onto C57BL/6) mice. Acoustic startle response, with prepulse inhibition, was
assessed as described (Vorhees et al., 2011). White noise background of
70 dB, prepulses of 73, 77, and 82 dB, and a mixed frequency startle stimulus
of 120 dB were used. Animals received 100 trials per day with equal numbers
of trials using a Latin square design that was duplicated. Animals were tested
on 2 consecutive days and the data from the second day were analyzed,
because animals that are tested on a single day for the acoustic startle
response tend to have greater variability that can mask group differences.
Human Brain Tissues
Brain specimens were described previously (Nordlund et al., 1995). Briefly,
NFI brains were obtained from patients diagnosed with NF1 based on NIH
guidelines. None of these patients showed any evidence of neurological disease other than NF1. Control/normal brains were obtained from adult patients
with no neurological diseases reported, although a history of depression was

Figure 6. Model of Nf1 Loss-Driven Myelin Decompaction
Increased MAPK/NO/Notch signaling may mediate myelin decompaction (gray-dotted arrows and insets), by downregulation of TJ/GJ proteins involved in myelin
compaction such as Claudin 11 (Cldn11), ZO-2 (Tjp2), and Connexin 26 (Gjb2) in pNf1 mutants.
(A) Decreased Nf1 (blue) results in increased RAS-GTP in mature oligodendrocytes, leading to hyperactive MAPK signaling (RTK / RAS / pMEK / pERK).
Production of NO increases in response to hyperactive MAPK pathway (NOS, dashed arrow). Subsequently, NO promotes directly or indirectly (dotted line) Notch
cleavage and translocation of NICD to the nucleus, where it regulates gene expression. Furthermore, diffusion of NO from Nf1 mutant oligodendrocytes (white
arrows) might affect nearby oligodendrocytes increasing the number of decompacted fibers (bottom). Either pharmacological treatment alone (MEKi, L-NAME or
GSI) rescues decompaction (purple lines).
(B) Absent Nf1 (red) results in accumulation of RAS-GTP and stronger induction (thick arrows) of MAPK signaling and NO production. It is possible that longlasting transcriptional and/or post-transcriptional changes (dotted lines with question marks) in molecules controlling NO levels (for example NOS1-2) might
contribute to increases in NO. Subsequently, NO promotes Notch activation and regulation of myelin genes. Combination of inhibitors (MEKi and L-NAME, purple
fused lines) rescues decompaction, while single agent treatments (for example GSI, fading purple arrow) improves severity but does not rescue decompaction.
Note that genetic inactivation of Notch (Figure 5) combined with MEKi or L-NAME, also rescues compaction in this setting.
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reported in one. All brains were harvested within 8 hr after death. Brains were
sliced and placed in 4% paraformaldehyde/0.1 M phosphate buffer for 72 hr
and prepared for paraffin embedding and storage.
Statistical Analysis
The minimal number of animals per statistically significant experiment was
three. Comparison between two groups used Student’s t tests with a significance cutoff of p < 0.05. Comparison of three or more groups used the oneway ANOVA, followed by Tukey post hoc test with a significance cutoff of
p < 0.05. For unbiased counting of myelinated axons, mice were randomized
and treated in a blinded manner. For behavior, acoustic startle was analyzed
by mixed linear Two-way ANOVA with factors of genotype and trial. Further
comparisons averaged across interval, day, and trial for genotype differences
were compared by (two-tailed) t test for independent samples.
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SUPPLEMENTAL EXPRERIMENTAL PROCEDURE

Figure S1 (related to Figure 1). Progressive Decrease in G-Ratio is Regulated by MAPK Signaling in pNf1
Mutants
Scattered plots (A) and bar graph (B) indicating g-ratio in the CC of WT, pNf1f/+ and pNf1f/f mice, at the indicated
months (mo) after tamoxifen treatment. g-ratio does not significantly change in WT animals between 1 and 8 mo (n=3,
4/time point); however, it is decreased in pNf1f/+ at 1 mo (n=3, ***P<0.001) and 6 mo (n=3, ****P<0.0001), and in
pNf1f/f at 1 mo (n=4, ***p<0.001) and 6 mo (n=3,****P<0.0001), as compared to WT animals. g-ratio is further
decreased in pNf1f/+ mutants from 1 to 6 mo (n=3/time point, ****P<0.0001), and presents a slight but significant
recovery in pNf1f/f from 1 to 6 mo (n=4,3/time point, *P<0.01). two-way ANOVA P<0.0001/Tukey Post Hoc. (B)
Number of myelin wraps does not significantly change in pNf1f/+ (6 mo) or pNf1f/f (1-8 mo), as compared to WT
animals (n=6,3/genotype, one-way ANOVA). (D) g-ratio in pNf1f/+ is rescued to WT levels following MEKi
treatment, but remains significantly decreased in pNf1f/f (n=3, P<0.0001). (E) Axon diameter does not significantly
change in WT animals between 1 and 8 mo (n=3,4/time point), but decreases in pNf1f/+ at 1 mo (n=3, ****P<0.0001)
and 6 mo (n=3, ****P<0.0001), and in pNf1f/f at 1 mo (n=4, ***P<0.001) and 6 mo (n=3, **P<0.01), as compared to
WT animals. Axon diameter presents significant recovery in pNf1f/f from 1 to 6 mo (n=4,3/time point, **P<0.01).
Two-way ANOVA/Tukey Post Hoc. (F) Immunostaining of EGFP (green) in the brain of PlpCreER;ccEGFP mice
indicates the number of recombinant cells in WT and pNf1f/f mutants at 6 months post-tamoxifen (6mo). DAPI
staining (blue) indicates nuclei of cells. (G) Quantification of EGFP+ cells in pNf1f/f and WT animals normalized to
area unit (left, 100k pixels) or total cells (right, DAPI+ cells), indicates no changes in the density of recombinant cells
(t test, 3 technical replicates, left; P=0.32, Right; P=0.23). All data are presented as the mean + s.e.m except in A (SD).
Scale bar=100 um.

Figure S2 (related to Figure 1). Effects of MEKi on pERK and levels of MBP in Nf1 mutants.
(A) Immunofluorescence of pERK (red cells, yellow arrows in magnifications) and CC1 (white) in vehicle- and MEKitreated WT and pNf1f/f mice, 1 month post-tamoxifen treatment. (B) Quantification of the percent of pERK+;CC1+
mOLs among total CC1+ cells indicates that the abnormal increased ERK activation in pNf1f/f mutants (data from
figure 1D) is significantly reduced by MEKi treatment (n=4,3/genotype, t-test, *P=0.0474). MEKi-treated pNf1f/f
mutants show, however, still significantly increased pERK+;CC1+ mOLs, as compared to MEKi-treated WT animals
(n=3/genotype, t-test, *P=0.0147). (C) Immunostaining showing similar expression levels of MBP (red) around CC1+
mOLs (white, arrows), in the CC of WT and pNf1f/f mutants. 1 mo; 1 month post-tamoxifen. Right: magnification of
squared area on the left. LV; lateral ventricle. Scale bar; 100um.

Figure S3 (related to Figure 2). Identity of Cells With Increased Notch Signaling in Nf1 mutants.
(A) Immunofluorescence of Hes5GFP (green) and GFAP (red) in coronal section of Nf1+/+;Hes5GFP mouse. Hes5+
cells correspond to GFAP+ astrocytes in the cortex (maginifcation 2, yellow arrows). Hes5+ cells correspond to GFAP+
astrocytes and unidentified GFAP- cells (white arrows, magnification 1) in the CC. (B) Immunostaining of pERK (red)
and Hes5GFP (green) in the CC of WT (top) and pNf1f/f (bottom) animals, 3 months (3mo) after tamoxifen treatment.
Hes5GFP signlas do not overlap with pERK in WT or pNf1f/f mutants. Instead, pERK signals are detected in CC1+
mOLs (white, arrows) in pNf1f/f mutants. See also Figure 1. Scale bar= 10 um. (C) Immunostaining of aNOTCH (red),
the reporter of recombination EGFP (green) and CC1 (white) in WT or Nf1 mutants carring the reporter allele pEGFP
(Plp1CreER;ccEGFP), 6 months after tamoxifen treatment. Magnification of the squared region in the CC of the
pNf1f/f mutant (bottom), shows aNOTCH signals in EGFP+ recombinant (arrow heads) as well as in EGFP- nonrecombinant (arrows) CC1+ mOLs. DAPI staining (blue) depicts cell nuclei. Scale bar; 5 um. In all panels: CC;corpus
callosum, Ctx; brain cortex, LV; lateral ventricle.

Figure S4 (related to Figures 2, 3 and 4). Myelin-Related Phenotypes in Nf1 Mutants Are Mimicked By Notch
Activation and Rescued By Inhibition Of Notch, MAPK and Nitric Oxide signal pathways.
(A) Quantification of myelinated axons indicates significantly decreased g-ratio in pNICD (PlpCreER;RosaNICD)
mice, as compared to WT mice (n=4, 5 mice/genotype, ****P<0.0001) 1 mo post-tamoxifen treatment. (B) WB
analysis of Claudin 11 and actin (loading control) from forebrain lysates of WT or pNICD mice, 1 month posttamoxifen (1mo). Densitometric analysis of Claudin 11 normalized to actin signals (bottom) indicates significantly
decreased Claudin 11 levels in pNf1 mutants (n=3 animals/genotype, t test, ***P=0.0005). (C) Genetic inactivation of
Notch signaling significantly increased g-ratio in pNf1f/f;Rbpj f/f double mutants, as compared to pNf1f/f mutants (n=
5,4/genotype, **P<0.001); however, g-ratio is still decreased when compared to WT animals (n=4, 6 mice/genotype,
****P<0.0001). The g-ratio of myelinated axons of pNf1f/+;Rbpjf/f double mutants increased, as compared to pNf1f/+
mutants (6 mo, n=3/genotype, ****P<0.0001), and was not significantly different from WT animals (n=3, 6
mice/genotype). One-way ANOVA, P<0.0001, Tukey post hoc test. (D) Evaluation of CC myelinated axons in pNf1
and WT mice indicates that GSI treatment results in: no effects on g-ratio of WT mice as compared to vehicle-treated
animals (1 mo, n=5/genotype, one-way ANOVA); increased g-ratio in pNf1f/f mutants as compared to vehicle-treated
pNf1f/f mutants (1 mo, n=5/genotype, one-way ANOVA, ****P<0.0001); and increased g-ratio in pNf1f/+ mutants,
as compared to vehicle-treated pNf1f/+ animals (6 mo, n=4,3/genotype, t-test, ****P<0.0001). (E) Dot plot
visualization of flow cytometry analysis showing Hes5GFP+ forebrain cells in WT (red) and pNf1f/f (blue) mice.
Although Hes5GFP+ cells increase in pNf1 mutants, as compared to WT (n=3/genotype, t-test, *P=0.0335), both
genotypes show negligible Hes5GFP+;NO+ or Hes5+;superoxide+ subpopulations (arrows). ns: no significant changes.
(F) Quantification of myelinated fibers indicates that abnormally decreased g-ratio in pNf1f/+ mutants is rescued by
L-NAME treatment for 7 days, as compared to vehicle-treated pNf1f/+ mutants (n=4,3/genotype, ****P<0.0001).
Abnormally low g-ratio in pNf1f/f mutants is increased after treatment with L-NAME, as compared to vehicle-treated
pNf1f/f mutants, (****n=3,5/genotype, P<0.0001), and fully rescued by concomitant treatment with L-NAME and
MEKi, as compared to WT animals (****n=6, 3/genotype, P<0.0001). One-way ANOVA P<0.0001, post hoc Tuckey
test).

Figure S5 (related to Figure 5). Increased Active Notch in NF1 Patients
(A) Immunodetection of activated Notch (aNOTCH) with a specific antibody (abcam ab8925) in the subcortical WM
(SCWM) of NF1-patient brains (n=2) and normal human brains (n=2). Representative aNOTCH signals are shown
with red arrows in magnification of squared areas. Scale bars 50 µm.

Figure S6 (related to Figure 2). Nf1 loss and Oligodendrocyte Numbers
(A) Immunostaining of Olig2+ (red) and Hes5GFP+ (green) cells in the CC of WT (top) and pNf1 f/f (bottom) mice, at
1 month (1mo) post-tamoxifen treatment. Increased Hes5GFP+ cells (bottom, right) are shown as a reference of the
mutant phenotype. Scale bar=200um. CC; corpus callosum, LV; lateral ventricle. (B) Quantification of Olig2+ cells
indicates no significant changes in pNf1 mutants, yet a trend toward increase in pNf1f/f animals (n= 3
animals/genotype, t test; WT vs pNf1f/f; P value= 0.18, WT vs pNf1f/+ P value= 0.48). (C) Dot-plot visualization of
flow cytometry analysis of the forebrain of WT (red) and pNf1f/f (blue) mice, showing PDGFRα+ and GalC+
populations. The percent of PDGFRα-GalC+ mOLs do not differ between WT and pNf1 mutants (bottom-right gates),
but PDGFRα+GalC+ and PDGFRα+GalC- (top gates) maturing OLs are increased. (D) Relative number (fold change
of WT) of forebrain Hes5GFP+ cells immunoreactive for PDGFRα, O4 and GalC, from flow cytometry analysis. The
population of PDGFRα+GalC+ maturing OLs are significantly increased in pNf1f/f animals (** P=0.001).

SUPPLEMENTARY EXPERIMENTAL PROCEDURES
Induced recombination in mice: For tamoxifen-induced recombination, adult mice (8–10 weeks old) were injected
intraperitoneally with tamoxifen (75 mg/kg of body weight, in sunflower seed oil; Sigma-Aldrich), twice daily for 4
consecutive days.
Mouse tissue for histology. Mice were anesthetized and perfused with 1X PBS followed by ice cold 4%
paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde overnight and sectioned using a
vibratome (Leica) or transferred to 20% sucrose for subsequent frozen sectioning.
Immunostaining and image analysis: Cryostat, vibratome floating, or paraffin-embedded sections (human samples)
were processed for immunodetection of proteins using specific antibodies for GFP (Millipore or Nacalai Tesque),
CC1 (Calbiochem) NICD (aNOTCH, Abcam and Cell signaling), GFAP (Invitrogen) and pERK (Cell Signaling),
Olig2 (Millipore) or MBP (Santa Cruz). Fluorophore-conjugated (Alexa 488, Alexa 568, Alexa 647; Invitrogen) or
HRP-conjugated (paraffin-embedded samples) secondary antibodies were used to detect the antigen-antibody
complexes. Using the appropriate laser excitation wavelength, images were captured on a Nikon C2 confocal
microscope. Manual and automated cell counting were performed using ImageJ and ITCN plugin, respectively.
Electron Microscopy: Wild type and experimental littermate mice were processed at the same time to minimize
myelin structure artifacts derived from processing. Animals were perfused with 4% paraformaldehyde/ 2.5%
glutaraldehyde, post–fixed in the same fixative overnight, and then the corpus callosum was transferred to 0.175M
cacodylate buffer, osmicated, dehydrated and embedded in Embed 812 (Ladd Research Industries). Ultrathin sections
were stained in uranyl acetate and lead citrate, and then imaged on a Hitachi Model H-7600 transmission electron
microscope.
Myelin Analysis: To quantify decompaction, myelin sheaths were rated as compact or decompacted, defined by fibers
with disruption of the myelin sheath (i.e. splitting of myelin lamellae). Severity of decompaction was evaluated, rating
decompact myelinated fibers with 1 (25%), 2 (25-50% disrupted), 3 (50-75% disrupted), or all 4 (>75% disrupted)
quadrants of the sheath disrupted. The g-ratio of myelinated fibers was obtained by dividing the diameter of each axon
by the fiber diameter (300-500 axons/animal, n=3–5 mice/genotype/condition), using ImageJ software. When a fiber
was identified as compact or 4 quadrants decompacted, 1 measurement was collected for g-ratio. When a fiber was
identified as 2 quadrants or 1 quadrant decompacted, 2 or 4 measurements were collected for g-ratio. Quantification
was carried out by blinded individuals.
Flow Cytometry: Mouse brains were processed for flow cytometry as previously described (Robinson et al., 2014).
Briefly, forebrains were dissociated using Accutase (Sigma-Aldrich) cell dissociation cocktail. ENZO Life Sciences
kits were used to detect Nitric Oxide (ENZ-51013-200) and Superoxide / Reactive Oxygen Species (ENZ-51010). A
positive control (L arginine, a nitric oxide synthase substrate) and a negative control (C-PTIO, a nitric oxide scavenger)
validated staining specificity for nitric oxide (Kalyanaraman et al., 2012). An inducer (pyocyanin) and inhibitor (nacetyl cysteine) were used for superoxide/reactive oxygen species positive and negative controls. Live/dead cell stain
(1:1,000; Invitrogen) and Annexin V (1:20, Life technologies) were used to detect apoptotic cells. For
oligodendrocyte-lineage analysis, antibodies recognizing glial progenitors (PDGFRα 1:50; Millipore), immature
oligodendrocytes (O4, 1:100; Millipore), mature oligodendrocytes (GalC 1:100; Millipore), astrocytes (GLAST, 1:10;
Miltenyi Biotec), endothelial cells (ICAM-1/CD54 1:200; Biolegend), and blood/microglia (CD45 1:100; BD
Biosciences) were used. Flow cytometry was performed using FacsDiva software for acquisition on an LSR II flow
cytometer using UV (355nm), violet (405 nm), blue (488 nm), red (640 nm), and yellow-green (561 nm) lasers.
Analysis was performed using FlowJo10 software. Compensation was completed using positive and negative controls
as well as fluorescent minus one (FMO) samples. Initial analysis was performed to gate on single (Forward Scatter FSC vs. Side Scatter - SSC), then on live (Dead Cell Stain Negative). Live CNS resident cells were gated to quantify
Hes5-GFP+ oligodendrocytes. To evaluate reactive oxygen species, geometric means were quantified for all CNS
resident cells (n=3 forebrains/ genotype/experiment).
Gene Expression Analysis: 1) Microarray analysis: Ninety percent confluent embryonic day 12.5 murine spinal
cord mixed glial precursor cultures were prepared from wild type and Nf1-/- mutant embryos, and maintained in
serum-free medium with N2 and B27 supplements on laminin coated dishes at 37 C, then stimulated for 5 minutes
with FGF2 as described (Bennett et al., 2003). Total RNA was isolated from passage 2-3 cells using Trizol reagent
(Invitrogen) followed by phenol/chloroform extraction and ethanol precipitation. RNA integrity was verified with an
Agilent Bio analyzer 2100, and cDNA synthesized (Superscript cDNA synthesis kit, Invitrogen) from 10ug RNA

using an oligo(dT) primer. Biotinylated double stranded product was hybridized to Affymetrix MOE430A Gene
Chip mouse oligonucleotide arrays. Microarray gene expression data was processed using Genespring 6.1 (Silicon
Genetics). To identify deregulated transcripts, genes that were ≥2 fold up- or down-regulated in Nf1-/- cultures as
compared to wild type were identified by Student’s t-test. (p<0.05). 2) RNAseq analysis: Total RNA was isolated
from optic nerves using Trizol reagent (Invitrogen) followed by chloroform extraction and purification by RNeasy
kit (Qiagen). Integrity of RNA was evaluated by Agilent Bioanalyzer 2100 (RIN>8.5) and cDNA was amplified by
Ovation system v2. RNA sequencing (35-40 million sequencing reads) was performed using paired-end BP flow
cell. RNA-Seq data was mapped to the reference genome mm10, and fold change and variance were calculated
using DESeq2 package in R. RT-PCR: qRT-PCR was carried out on glial progenitor RNA from E12.5 spinal cord
cultures in triplicate after FGF2 stimulation using primers for DII-1 R2409 =CCATAGTGCAATGGGAACAAC/
L2229 = CAAGGATATAGCCCCGATGA, Dll-3 R= CTACAGCGGTCCACCCTCTT, L919
=ATTCTACGGGCTTCGATGTG, and Hes5 R=AGAGGGTGGGCCCTGATTA, L=
AGGATGAGCTCGTTCCTCTG. Mouse Gapdh primers were used for normalization, and the delta-delta Ct method
used for quantification.
Western Blot: E12.5 murine spinal cord cultures treated with FGF2 for 5 minutes (Bennett et al., 2003), or forebrain
tissue, were lysed in RIPA buffer. Cell sample lysates were sonicated and clarified through centrifugation. Protein
(50-100 µg) was separated on SDS-polyacrylamide gradient gels (ISC BioExpress) through electrophoresis and
transferred to polyvinylidene difluoride membrane (Bio-Rad). Membranes were probed with rabbit anti-Notch1 (Santa
Cruz C20R; sc-6014-R) at 1:200, anti-Ras10 (Upstate Biotechnology) and anti-Claudin-11 (Invitrogen) at 1:1,000.
Horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) were used to detect signal with Enhanced
Chemiluminescence (ECL) Plus developing system (Amersham Biosciences).
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